Login Here


Register
 
Search


 Russell Publishing Ltd
 Court Lodge
 Hogtrough Hill
 Brasted
 Kent TN16 1NU. UK
 Registered in England 
 No. 2709148
 Registered office as above.
 VAT No. GB 577 897847

 

Roundtable: The future direction for clinical trials

publication date: Sep 21, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Success rates for the development of new drugs is very low across all therapeutic areas and is lowest for oncology with only five per cent of compounds going into Phase I making it to market1. It is therefore important for Phase I and II trials to be better at distinguishing those agents that are going to succeed and those that are not. Costs of new drugs are growing and it is important to be able to focus resources on those that are most likely to make it all the way.



Sorry, this page is available to members only.

If you have not registered with us yet, why not register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.

Why should I register online with European Pharmaceutical Review?

You will receive . . .

* Up to date information on all latest technologies in drug development and manufacturing

* Exciting new features, interviews, updates and profiles

* All latest developments, news and innovations

* Information on projects that your industry colleagues are involved in

* Exclusive access our back issue archive